Eli Lilly and Novo Nordisk have both assuaged investor concerns over near-term growth. Now the focus shifts back to their ...

Allowing such medications as options could lead to significant savings from improved health, writes Kelley Koch.

The economic burden of obesity is also significant. In the Finger Lakes, excess medical spending due to obesity is estimated ...

Recognizing obesity as a chronic disease can improve treatment, address complications, and reshape healthcare strategies for ...

Obesity medication prescriptions reached 1.5 million, driven by GLP-1 agents semaglutide and tirzepatide, as public interest ...